Movement Disorder and Neuromodulation Unit, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany.
Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Mitte, Berlin, Germany.
Eur J Neurol. 2021 May;28(5):1566-1573. doi: 10.1111/ene.14737. Epub 2021 Feb 6.
Observational study to evaluate long-term effects of deep brain stimulation (DBS) of the globus pallidus internus (GPi) and the ventral intermediate thalamic nucleus (VIM) on patients with medically refractory myoclonus dystonia (MD).
More recently, pallidal as well as thalamic DBS have been applied successfully in MD but long-term data are sparse.
We retrospectively analyzed a cohort of seven MD patients with either separate (n = 1, VIM) or combined GPi- DBS and VIM-DBS (n = 6). Myoclonus, dystonia and disability were rated at baseline (BL), short-term (ST-FU) and long-term follow-up (LT-FU) using the United Myoclonus Rating Scale, Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) and Tsui rating scale, respectively. Quality of life (QoL) and mood were evaluated using the SF-36 and Beck Depression Inventory questionnaires, respectively.
Patients reached a significant reduction of myoclonus at ST-FU (62% ± 7.3%; mean ± SE) and LT-FU (68% ± 3.4%). While overall motor BFMDRS changes were not significant at LT-FU, patients with GPi-DBS alone responded better and predominant cervical dystonia ameliorated significantly up to 54% ± 9.7% at long-term. Mean disability scores significantly improved by 44% ± 11.4% at ST-FU and 58% ± 14.8% at LT-FU. Mood and QoL remained unchanged between 5 and up to 20 years postoperatively. No serious long-lasting stimulation-related adverse events were observed.
We present a cohort of MD patients with very long follow-up of pallidal and/or thalamic DBS that supports the GPi as the favourable stimulation target in MD with safe and sustaining effects on motor symptoms (myoclonus>dystonia) and disability.
观察性研究评估深部脑刺激(DBS)对苍白球 internus(GPi)和腹侧中间丘脑核(VIM)对药物难治性肌阵挛性肌张力障碍(MD)患者的长期影响。
最近,苍白球和丘脑 DBS 已成功应用于 MD,但长期数据稀缺。
我们回顾性分析了 7 例 MD 患者的队列,其中 1 例为单独(n=1,VIM)或联合 GPi-DBS 和 VIM-DBS(n=6)。使用联合肌阵挛评分量表、伯克-法恩-马尔丹肌张力障碍评分量表(BFMDRS)和 Tsui 评分量表,分别在基线(BL)、短期(ST-FU)和长期随访(LT-FU)评估肌阵挛、肌张力障碍和残疾。使用 SF-36 和贝克抑郁量表分别评估生活质量(QoL)和情绪。
患者在 ST-FU(62%±7.3%;平均值±SE)和 LT-FU(68%±3.4%)时达到肌阵挛的显著减少。尽管 LT-FU 时整体运动 BFMDRS 变化不显著,但单独接受 GPi-DBS 的患者反应更好,主要的颈部肌张力障碍显著改善,高达 54%±9.7%。ST-FU 时残疾评分平均改善 44%±11.4%,LT-FU 时改善 58%±14.8%。术后 5 年至 20 年,情绪和 QoL 保持不变。未观察到严重的长期与刺激相关的不良事件。
我们提供了一组 MD 患者的长期随访,支持 GPi 作为 MD 的有利刺激靶点,对运动症状(肌阵挛>肌张力障碍)和残疾具有安全和持续的效果。